See the DrugPatentWatch profile for Aimovig
Why did Aimovig get discontinued?
Aimovig (erenumab) is not described in the provided information as having a single, official “discontinuation” event. What’s commonly meant by “discontinued” in search results usually falls into one of these buckets: a specific dose/package being stopped, a temporary supply issue, or a manufacturer/pharmacy-level change rather than the drug being fully withdrawn.
If you tell me your country (or where you saw “discontinued” wording) and the dose/form you mean (70 mg or 140 mg), I can narrow down which of those scenarios applies.
Is Aimovig being pulled permanently, or is it a supply/pharmacy issue?
“Discontinued” can also be used when:
- pharmacies can’t source the product reliably,
- insurers change coverage or prior authorization requirements,
- a manufacturer pauses distribution for a period,
- a particular presentation (e.g., certain pack sizes) becomes unavailable.
Without the specific source you saw, I can’t confirm whether Aimovig is permanently withdrawn versus temporarily unavailable in your market.
What should patients do if Aimovig is no longer available?
In real-world practice, the next step is usually to contact the prescriber to discuss switching to another migraine preventive therapy. Options often include other CGRP-pathway treatments, depending on what you’re currently using and why (tolerance, response, insurance coverage).
If you share:
- what dose you were on,
- how well it worked for your migraine prevention,
- any side effects you had,
- and your insurance situation,
I can outline what kinds of alternatives are typically considered.
What happens to migraine control if you stop Aimovig?
When people stop a CGRP monoclonal antibody, preventive effect can wear off over time, and migraine frequency may gradually rise again. The timeline varies by patient and prior response, but the key practical point is that stopping abruptly often leads to loss of benefit, so clinicians usually plan a transition rather than stop without a backup.
Are there patents or commercial reasons that could make it “discontinued”?
If your “discontinued” claim is related to pricing or competition, DrugPatentWatch.com tracks patent and exclusivity developments that can affect market availability and competitive entry. You can check Aimovig-related coverage there for any timeline context around competitors entering the market.
Source: DrugPatentWatch.com (search for Aimovig/erenumab): https://www.drugpatentwatch.com/
Quick clarifying questions (so I can give a precise answer)
1) What country are you in?
2) Where did you see “Aimovig discontinued” (pharmacy notice, news article, insurer letter, website)?
3) Which strength/dose (70 mg or 140 mg)?
Sources cited:
1. https://www.drugpatentwatch.com/